Home › Focal Segmental Glomerulosclerosis › Georgia › Atlanta
Focal Segmental Glomerulosclerosis clinical trials in Atlanta, GA
5 studies for Focal Segmental Glomerulosclerosis are looking for participants at sites in and around Atlanta (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
RecruitingPhase 2
- Emory Children's Center- Site Number : 8400020, Atlanta
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
RecruitingPhase 3
- Emory Children's Center, Atlanta
- Southeast Kidney Associates - East Point, East Point · 6 mi away
NEPTUNE Match Study
Recruiting
- Emory University Hospital - Children's Hospital of Atlanta, Atlanta
Nephrotic Syndrome Study Network
RecruitingObservational study
- Emory University and Children's Healthcare of Atlanta, Atlanta
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
RecruitingPhase 3
- Emory University School of Medicine, Atlanta
Focal Segmental Glomerulosclerosis trials in other cities
- Philadelphia, PA9 studies
- Durham, NC8 studies
- New York City, NY7 studies
- Miami, FL6 studies
- Queens, NY6 studies
- Los Angeles, CA6 studies
- Ann Arbor, MI6 studies
- Houston, TX5 studies
- Kansas City, MO4 studies
- Cleveland, OH4 studies
- Chicago, IL4 studies
- Dallas, TX4 studies
Other studies in Atlanta
- Cancer (all types)50 studies
- Non-Small Cell Lung Cancer46 studies
- Breast Cancer41 studies
- Multiple Myeloma41 studies
- Prostate Cancer32 studies
- Lung Cancer29 studies
- Acute Myeloid Leukemia29 studies
- Colorectal Cancer29 studies
- Ovarian Cancer28 studies
- Metastatic Cancer27 studies
- Heart Failure25 studies
- Obesity25 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.